Yardimci Aytul Hande, Sel Ipek, Bektas Ceyda Turan, Yarikkaya Enver, Dursun Nevra, Bektas Hasan, Afsar Cigdem Usul, Gursu Rıza Umar, Yardimci Veysi Hakan, Ertas Elif, Kilickesmez Ozgur
Department of Radiology, Istanbul Training and Research Hospital, Kasap İlyas Mah., Org. Abdurrahman Nafiz Gürman Cd., Fatih, 34098, Istanbul, Turkey.
Department of Pathology, Istanbul Training and Research Hospital, Istanbul, Turkey.
Jpn J Radiol. 2020 Jun;38(6):553-560. doi: 10.1007/s11604-020-00936-2. Epub 2020 Mar 5.
The aim of the study is to explore the role of computed tomography texture analysis (CT-TA) for predicting clinical T and N stages and tumor grade before neoadjuvant chemotherapy treatment in gastric cancer (GC) patients during the preoperative period.
CT images of 114 patients with GC were included in this retrospective study. Following pre-processing steps, textural features were extracted using MaZda software in the portal venous phase. We evaluated and analyzed texture features of six principal categories for differentiating between T stages (T1,2 vs T3,4), N stages (N+ vs N-) and grades (low-intermediate vs. high). Classification was performed based on texture parameters with high model coefficients in linear discriminant analysis (LDA).
Dimension-reduction steps yielded five textural features for T stage, three for N stage and two for tumor grade. The discriminatory capacities of T stage, N stage and tumor grade were 90.4%, 81.6% and 64.5%, respectively, when LDA algorithm was employed.
CT-TA yields potentially useful imaging biomarkers for predicting the T and N stages of patients with GC and can be used for preoperative evaluation before neoadjuvant treatment planning.
本研究旨在探讨计算机断层扫描纹理分析(CT-TA)在预测胃癌(GC)患者术前新辅助化疗前的临床T和N分期以及肿瘤分级中的作用。
本回顾性研究纳入了114例GC患者的CT图像。经过预处理步骤后,在门静脉期使用MaZda软件提取纹理特征。我们评估并分析了六个主要类别的纹理特征,以区分T分期(T1,2与T3,4)、N分期(N+与N-)和分级(低-中级与高级)。基于线性判别分析(LDA)中具有高模型系数的纹理参数进行分类。
降维步骤产生了用于T分期的五个纹理特征、用于N分期的三个纹理特征和用于肿瘤分级的两个纹理特征。采用LDA算法时,T分期、N分期和肿瘤分级的鉴别能力分别为90.4%、81.6%和64.5%。
CT-TA可为预测GC患者的T和N分期产生潜在有用的成像生物标志物,并可用于新辅助治疗计划前的术前评估。